The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

In this post-hoc analysis, compared with placebo, canagliflozin reduced serum urate concentration and also reduced events related to gout flare among patients with type 2 diabetes. A trial explicitly designed to test the effects of sodium glucose co-transporter 2 inhibition on gout is required to confirm these observations.

Read the full article here

Related Articles